Inclusion Criteria:

- Participant was previously diagnosed with multiple myeloma based on standard criteria
and had measurable disease. Measurable disease for secretory multiple myeloma was
defined as any quantifiable serum M-protein value (generally, but not exclusively,
greater than (>) 1 gram per deciliter (g/dL) immunoglobulin (Ig) G Myeloma protein
(M-protein) and >0.5 g/dL Ig A) or urine light-chain excretion of equal to (=) or
>200 milligram (mg)/24 hour

- Participant previously tolerated 1.0 or 1.3 mg/metersquare (m^2) bortezomib alone or
in combination with other agents and had complete response (CR) or partial response
(PR) upon completion of bortezomib therapy

- It had been greater than or equal to (>=) 6 months since the participant's last
bortezomibdose and the participant had progressive disease (PD) if prior response to
bortezomib was PR or the participant had relapsed from CR

- Participant had a life expectancy >3 months

- If female, the participant was either postmenopausal or surgically sterilized or
willing to use an acceptable method of birth control from screening through at least
30 days after completion of the last cycle

Exclusion Criteria:

- Participant had received chemotherapy, radiotherapy, antibody, immunotherapy, or
experimental therapy to treat multiple myeloma since their last dose of bortezomib.
Note: participants could have received localized palliative radiotherapy for
complications due to osteolytic bone lesions. Participants could have received
steroids (dexamethasone or equivalent) or thalidomide or interferon as maintenance
therapy since their last dose of bortezomib according to local standard of care. In
addition, participants could have received a cumulative dose of up to 160 mg
dexamethasone or equivalent as emergency therapy within 4 weeks prior to enrolment.
Participants could have received high dose therapy/stem cell transplantation after
induction regimen containing bortezomib, but only if PR or CR was observed during
bortezomib containing induction therapy

- Participant had uncontrolled or severe cardiovascular disease, including myocardial
infarction within 6 months of enrolment or had New York Heart Association Class III
or IV heart failure, uncontrolled angina, clinically significant pericardial disease,
severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute
ischemia or active conduction system abnormalities

- Participant had poorly controlled hypertension, diabetes mellitus, or other serious
medical or psychiatric illness that could potentially interfere with the completion
of treatment according to the protocol

- Participant had another malignancy within the past 5 years. Exceptions were made for
the following if they were treated and not active: basal cell or non-metastatic
squamous cell carcinoma of the skin, cervical carcinoma in situ or International
Federation of Gynecology and Obstetrics Stage 1 carcinoma of the cervix

- Patient has an uncontrolled or severe cardiovascular disease, within 6 months of
enrolment

- Female participant was pregnant or breast feeding. Confirmation that the participant
was not pregnant was to be established by a negative beta human chorionic
gonadotropin pregnancy test result obtained during the Screening period. Pregnancy
testing was not required for post menopausal or surgically sterilized women.